Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Early Phase 1

2(33.3%)

6Total

Phase 1(4)

Early Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05636618Phase 1Recruiting

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

Role: lead

NCT06710756Phase 1Recruiting

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Role: lead

NCT05655312Phase 1Recruiting

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Role: lead

NCT06148636Early Phase 1Active Not Recruiting

A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

Role: collaborator

NCT05111509Early Phase 1Active Not Recruiting

A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

Role: collaborator

NCT04904120Phase 1Completed

Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy

Role: lead

All 6 trials loaded